Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

30.9K
Overview
30.9K
Affinity and Avidity01:41

Affinity and Avidity

35.7K
Overview
35.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Finding the Goldilocks zone: Modulating glycoprotein cleavage and fusogenicity optimizes the efficacy of a candidate Crimean-Congo hemorrhagic fever virus vaccine.

bioRxiv : the preprint server for biology·2026
Same author

Vertical transmission of Nipah virus in an experimentally infected nonhuman primate; a brief report and description of histopathological lesions.

The Journal of infectious diseases·2026
Same author

Marburg virus disease: a comprehensive review.

Clinical microbiology reviews·2026
Same author

Recombinant Bombali ebolavirus in cynomolgus macaques as a survival model of Ebola virus disease.

Nature communications·2026
Same author

Hemorrhagic Fever Disease in STAT-1 Knockout Mice Infected with Lujo Virus.

Pathogens (Basel, Switzerland)·2026
Same author

Analysis of Recombinant Cedar Virus Infection and Cross-Protection Against Related Henipaviruses in African Green Monkeys.

Viruses·2026

Related Experiment Video

Updated: May 11, 2025

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
04:47

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

Published on: February 23, 2018

7.6K

High-Avidity Anti-Filovirus IgG Elicited Using Protein Subunit Vaccines Does Not Correlate with Protection.

Caitlin A Williams1, Teri Ann S Wong1, Michael M Lieberman1

  • 1Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96813, USA.

Immuno
|April 17, 2025
PubMed
Summary
This summary is machine-generated.

Understanding antibody avidity in Ebola virus vaccines is crucial for developing effective strategies, especially for vulnerable populations. This study investigates antibody avidity as a key correlate of protection against Ebola virus disease.

Keywords:
avidityfilovirusnonhuman primatesvaccines

More Related Videos

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination
08:13

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Published on: January 20, 2019

21.4K
An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers
06:34

An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers

Published on: December 1, 2017

35.7K

Related Experiment Videos

Last Updated: May 11, 2025

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
04:47

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

Published on: February 23, 2018

7.6K
Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination
08:13

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Published on: January 20, 2019

21.4K
An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers
06:34

An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers

Published on: December 1, 2017

35.7K

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Zaire ebolavirus (EBOV) and Sudan ebolavirus pose significant public health threats due to high fatality rates and epidemic potential.
  • Challenges in studying Ebola virus disease (EVD) include species specificity for animal models and high biosafety level requirements.
  • Current understanding of protective immune responses and vaccine correlates of protection (vCOP) for EBOV vaccines remains incomplete, limiting vaccination strategies for vulnerable groups.

Purpose of the Study:

  • To investigate vaccine-elicited antibody avidity as a potential correlate of protection against EBOV.
  • To further characterize the role of antibody avidity in both protective and non-protective vaccine responses.

Main Methods:

  • The study focused on analyzing antibody avidity elicited by vaccines.
  • Investigated the contribution of antibody avidity to protective and non-protective immune responses.

Main Results:

  • Vaccine-elicited antibody avidity was explored as a potential correlate of protection.
  • The research aimed to elucidate the specific contribution of antibody avidity in vaccine efficacy.

Conclusions:

  • Understanding antibody avidity is critical for defining vaccine correlates of protection (vCOP).
  • This knowledge is essential for developing improved EBOV vaccination strategies, particularly for high-risk populations.